| Autor: |
Chan Pin Yin DRPP; Department of Cardiology, St. Antonius Hospital, 3435 CM Nieuwegein, The Netherlands., Vos GA; Department of Cardiology, St. Antonius Hospital, 3435 CM Nieuwegein, The Netherlands., van der Sangen NMR; Department of Cardiology, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, 1105 AZ Amsterdam, The Netherlands., Walhout R; Department of Cardiology, Hospital Gelderse Vallei, 6716 RP Ede, The Netherlands., Tjon Joe Gin RM; Department of Cardiology, Rijnstate Hospital, 6815 AD Arnhem, The Netherlands., Nicastia DM; Department of Cardiology, Gelre Hospitals, 7334 DZ Apeldoorn, The Netherlands., Langerveld J; Department of Cardiology, Rivierenland Hospital, 4002 WP Tiel, The Netherlands., Claassens DMF; Department of Cardiology, St. Antonius Hospital, 3435 CM Nieuwegein, The Netherlands., Gimbel ME; Department of Cardiology, St. Antonius Hospital, 3435 CM Nieuwegein, The Netherlands., Azzahhafi J; Department of Cardiology, St. Antonius Hospital, 3435 CM Nieuwegein, The Netherlands., Bor WL; Department of Cardiology, St. Antonius Hospital, 3435 CM Nieuwegein, The Netherlands., Oirbans T; Department of Cardiology, St. Antonius Hospital, 3435 CM Nieuwegein, The Netherlands., Dekker J; Department of Cardiology, St. Antonius Hospital, 3435 CM Nieuwegein, The Netherlands., Vlachojannis GJ; Department of Cardiology, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands., van Bommel RJ; Department of Cardiology, Tergooi Hospital, 1261 AN Blaricum, The Netherlands., Appelman Y; Department of Cardiology, Amsterdam UMC, VU University, Amsterdam Cardiovascular Sciences, 1081 HV Amsterdam, The Netherlands., Henriques JPS; Department of Cardiology, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, 1105 AZ Amsterdam, The Netherlands., Kikkert WJ; Department of Cardiology, Onze Lieve Vrouwe Gasthuis, 1091 AC Amsterdam, The Netherlands., Ten Berg JM; Department of Cardiology, St. Antonius Hospital, 3435 CM Nieuwegein, The Netherlands. |
| Abstrakt: |
Diagnostic and treatment strategies for acute coronary syndrome have improved dramatically over the past few decades, but mortality and recurrent myocardial infarction rates remain high. An aging population with increasing co-morbidities heralds new clinical challenges. Therefore, in order to evaluate and improve current treatment strategies, detailed information on clinical presentation, treatment and follow-up in real-world patients is needed. The Future Optimal Research and Care Evaluation in patients with Acute Coronary Syndrome (FORCE-ACS) registry (ClinicalTrials.gov Identifier: NCT03823547) is a multi-center, prospective real-world registry of patients admitted with (suspected) acute coronary syndrome. Both non-interventional and interventional cardiac centers in different regions of the Netherlands are currently participating. Patients are treated according to local protocols, enabling the evaluation of different diagnostic and treatment strategies used in daily practice. Data collection is performed using electronic medical records and quality-of-life questionnaires, which are sent 1, 12, 24 and 36 months after initial admission. Major end points are all-cause mortality, myocardial infarction, stent thrombosis, stroke, revascularization and all bleeding requiring medical attention. Invasive therapy, antithrombotic therapy including patient-tailored strategies, such as the use of risk scores, pharmacogenetic guided antiplatelet therapy and patient reported outcome measures are monitored. The FORCE-ACS registry provides insight into numerous aspects of the (quality of) care for acute coronary syndrome patients. |
